When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Wegovy's heart benefits due to more than weight loss ... - AOL

   www.aol.com/news/novo-nordisk-says-wegovy-heart...

   Drug regulators can update the information on medicine labels to include new data or reflect new indications for use after initial approval. U.S. and UK drug regulators approved Eli Lilly's rival ...

3. FDA Approves Popular Weight Loss Drug for Heart Disease ... - AOL

   www.aol.com/fda-approves-popular-weight-loss...

   The medication was previously only FDA-approved for weight loss, but can now be marketed for cardiovascular disease. Wegovy lowered the risk of heart events by 20% in people with a history of ...

4. Popular weight loss drug found to reduce risk of heart ... - AOL

   www.aol.com/popular-weight-loss-drug-found...

   Taking a weight loss drug may also help reduce the risk of heart attack, stroke and cardiac death, data shows. Wegovy, a drug approved by the U.S. Food and Drug Administration to treat obesity ...

5. Anti-obesity medication - Wikipedia

   en.wikipedia.org/wiki/Anti-obesity_medication

   The United States Food and Drug Administration and the European Medicines Agency have approved weight loss medications for adults with either a body-mass index (BMI) of at least 30, or a body-mass index of at least 27 with at least one weight-related comorbidity. This patient population is considered to have sufficiently high baseline health ...

6. GLP-1 receptor agonist - Wikipedia

   en.wikipedia.org/wiki/GLP-1_receptor_agonist

   GLP-1 agonists were initially developed for type 2 diabetes. [5] The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include GLP-1 agonists or SGLT2 inhibitors as a first-line pharmacological therapy for type 2 diabetes in patients who have or are at high risk for atherosclerotic cardiovascular disease or heart failure.

7. Obesity drug Wegovy is approved to cut heart attack and ...

   www.aol.com/news/obesity-drug-wegovy-approved...

   The weight-loss drug typically costs about $1,300 a month. Novo Nordisk has also asked European Union regulators to expand the use of the drug for heart problems. EU regulators have not weighed in ...